Results 71 to 80 of about 21,293 (203)

Accelerating Generic Long‐Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to Access

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1195-1204, May 2026.
The global HIV response aims for widespread availability of affordable, quality‐assured long‐acting antiretroviral (LA ARV) drugs to achieve sustained epidemic control, particularly in low‐ and middle‐income countries. This report summarizes key discussion points, findings, and outcomes from an international workshop on generic LA ARVs, held in ...
Usman Arshad, Lobna Gaayeb, Henry Pertinez, Rajith K. R. Rajoli, Melynda Watkins, Parag Nimbolkar, Simone Perazzolo, Bharat Pagi, Annemarie Wensing, Saye Khoo, Marta Boffito, René Holm, Zack Panos, Imelda Mahaka, Francois Venter, Benny Kottiri, Keith W. Crawford, Rodney J. Y. Ho, Polly Clayden, Paul Domanico, Kimberly Struble, Andrew Owen, Charles Flexner   +22 more
wiley   +1 more source

Acquired Fanconi Syndrome from Tenofovir Treatment in a Patient with Hepatitis B

Case Reports in Hepatology, 2023
Fanconi syndrome is a rare disease of generalized proximal tubule dysfunction which can be acquired secondary to certain medications, including tenofovir, a commonly used hepatitis B treatment.
Shirley X. Jiang, John Duncan, Hin Hin Ko   +2 more
doaj   +1 more source

A Phase 2b randomised, controlled, partially blinded trial of the HIV Nucleoside Reverse Transcriptase Inhibitor BMS-986001 (AI467003): Weeks 24 and 48 Efficacy, Safety, Bone and Metabolic Results [PDF]

, 2016
Background BMS-986001 is a thymidine analogue nucleoside reverse transcriptase inhibitor (NRTI) designed to maintain in-vitro antiviral activity while minimising off-target effects.
Avihingsanon, Anchalee, Echevarría, Juan, Gupta, Samir K., Hanna, George J., Joshi, Samit R., Lataillade, Max, Lombaard, John, McComsey, Grace A., Orrell, Catherine, Osiyemi, Olayemi, Ray, Neelanjana, Santoscoy, Mario, Stock, David A.   +12 more
core   +1 more source

Cancer risks and trends between 1997 and 2018, and effects of restored immunity in people living with HIV: Results from the ANRS CO4 French hospital database on HIV

International Journal of Cancer, Volume 158, Issue 9, Page 2298-2308, 1 May 2026.
What's new? This large nation‐wide cohort study provides a comprehensive 20‐year analysis of cancer trends among people living with HIV in France, highlighting persistent excess risks for virus‐related cancers despite effective antiretroviral therapy and immune restoration.
Sophie Grabar, Paula Lakrout, Valérie Potard, Aurélien Belot, Jacques Cadranel, Christine Jacomet, Christine Katlama, Esaïe Marshall, Olivier Lambotte, Romain Palich, Sylvie Ronot‐Bregigeon, Jean‐Philippe Spano, Anne‐Marie Bouvier, Alain Makinson, Dominique Costagliola   +14 more
wiley   +1 more source

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. [PDF]

, 2016
BACKGROUND: Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP).
TenoRes Study Group
core   +2 more sources

KSHV Genome in Saliva, Whole Blood and Kaposi's Sarcoma Biopsy Specimens in Republic of Congo: Phylogenetic Analysis and an APOBEC3B Mutational Signature

Journal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT Kaposi's sarcoma‐associated herpesvirus (KSHV) has been associated with a variety of diseases and is endemic in Sub‐Saharan Africa. We performed KSHV‐whole‐genome analysis and search for APOBEC‐editing to describe genetic diversity in samples issued from an endemic region.
Gervillien Arnold Malonga, Valentin Leducq, Antoine Fauchois, Dimitry Moudiongui Mboungou Malanda, Patrina Joseph Iloukou Mayakia, Juthèce Private Malanda‐Kiminou, Ferdinand Emaniel Brel Got, Fabien Gaël Mouamba, Vincent Calvez, Jean Felix Peko, Anne‑Geneviève Marcelin, Aude Jary   +11 more
wiley   +1 more source

Fanconi Syndrome Due to Tenofovir Disoproxil Fumarate in a Patient with Chronic Hepatitis B Induced Cirrhosis: A Case Report

Case Reports in Clinical Practice
We present a 63-year-old woman with chronic hepatitis B. The patient has a history of cirrhosis due to chronic hepatitis B and is under treatment with Tenofovir disoproxil fumarate.
Milad Khodabakhshi, Behshad Pazooki
doaj   +1 more source

Development and validation of a stability-indicating lc method for the determination of tenofovir disoproxil fumarate in pharmaceutical formulation [PDF]

, 2012
The present study describes the degradation of tenoforvir disoproxil fumarate (teno) under different prescribed stressconditions (hydrolysis, oxidation, dry and wet heat and photolysis) following the International Conference on Harmonization and ...
Shweta Havele, Sunil R. Dhaneshwar
core  

Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study. [PDF]

, 2017
Rilpivirine is safe and effective in HIV-naïve patients with low baseline HIV-RNA or in switch strategy. It offers the advantages of few drug-drug interactions and a favourable toxicity profile.
Battegay, Manuel, Bernasconi, Enos, Calmy, Alexandra, Cavassini, Matthias, Fehr, Jan, Gayet-Ageron, Angèle, Hirzel, Cedric, Schmid, Patrick, Sculier, Delphine, Swiss HIV Cohort Study   +9 more
core   +5 more sources

Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Virus Infection in the High‐Replicative Low‐Inflammatory Phase: A 48‐Week Randomized Controlled Trial

Journal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT Antiviral treatment for chronic HBV infection in the “high‐replicative low‐inflammatory” phase has not been widely recommended. This study aimed to evaluate the safety and efficacy of antiviral therapy in this patient population and analyze peripheral immunological characteristics in relation to treatment response.
Qiumin Luo, Ruixuan Xu, Yeqiong Zhang, Wenxiong Xu, Xiangyong Li, Jing Lai, Jianguo Li, Xingrong Zheng, Hong Deng, Lubiao Chen, Xiang Zhu, Chan Xie, Liang Peng   +12 more
wiley   +1 more source